Combined Hamartoma of the Retina

Combined hamartoma of the retina and retinal pigment epithelium (often abbreviated CHR-RPE or simply CHRRPE) is a rare, benign, congenital ocular tumor. It consists of an overgrowth of tissues normally present in the retina—glial cells, vascular elements, and retinal pigment epithelial (RPE) cells—but arranged in a disorganized mass. Clinically, CHRRPE typically appears as a slightly elevated, grey-white lesion at the posterior pole (often peripapillary), though it can also arise in the macula or peripheral retina. Over time, it may induce traction on the retinal surface (forming an epiretinal membrane), distort retinal vessels, and lead to vision changes. NCBIMalaCards

Combined hamartoma of the retina and retinal pigment epithelium (CHRRPE) is a rare, benign congenital ocular lesion characterized by disorganized proliferation of glial, vascular, and pigmented epithelial cells within the retina and underlying retinal pigment epithelium. Clinically, it appears as a slightly elevated, greyish lesion at the posterior pole, often accompanied by an epiretinal membrane that can distort retinal vessels and lead to tractional changes such as macular edema, macular holes, or retinal detachment in severe cases PMCPMC. Histopathologically, CHRRPE consists of intermingled sheets of retinal glial tissue, convoluted vessels, and patches of pigmented epithelial cells with duplications of the RPE layer BioMed Central. Patients typically present in childhood with reduced visual acuity or strabismus, though atypical cases—sometimes associated with syndromes like Neurofibromatosis Type 2—may be misdiagnosed without multimodal imaging such as fundus fluorescein angiography or optical coherence tomography PMCPMC.

Types

A practical clinical classification was proposed by Dedania and colleagues, based on (1) tumor location—zone 1 (posterior pole/peripapillary), zone 2 (mid-periphery), or zone 3 (far periphery)—and (2) morphological features on optical coherence tomography (presence of epiretinal membrane, partial versus full-thickness retinal involvement, tractional retinoschisis, or retinal detachment). This zonal-and-stage system guides both follow-up frequency and decisions regarding surgical intervention. PubMed

---

Causes

1. Developmental Anomaly of RPE Progenitor Cells
   CHRRPE is believed to originate during ocular development when undifferentiated progenitor cells destined for the retinal pigment epithelium fail to complete normal maturation, leading to focal hyperplasia and disorganized tissue growth within the neurosensory retina. EyeWiki

2. Sporadic Somatic Mutations
   In most cases, CHRRPE arises sporadically without a clear inherited pattern, likely due to a somatic mutation occurring in retinal progenitor cells during gestation. PMC

3. Neurofibromatosis Type 2 (NF2)
   Bilateral CHRRPE or multifocal lesions have been reported in children with NF2, making CHRRPE a recognized ocular manifestation of this neurocutaneous disorder. PubMed

4. Neurofibromatosis Type 1 (NF1)
   Although less common than NF2, CHRRPE has also been observed in patients with NF1, implicating shared pathways of neural crest–derived cell proliferation. EyeWiki

5. Tuberous Sclerosis Complex (TSC)
   As with other retinal hamartomas, CHRRPE may occur in TSC, where mutations in TSC1 or TSC2 lead to dysregulated cell growth and hamartomatous lesions. PMC

6. Gorlin–Goltz Syndrome (Basal Cell Nevus Syndrome)
   Case reports link CHRRPE with Gorlin syndrome, suggesting that PTCH1 mutations may predispose to a wider spectrum of hamartomatous growths, including in the retina. EyeWiki

7. Branchio-Oculo-Facial Syndrome
   Rare associations with this developmental syndrome indicate that CHRRPE can arise alongside craniofacial and branchial arch anomalies. EyeWiki

8. Brachio-Oto-Renal (BOR) Syndrome
   Though exceptionally rare, CHRRPE has been documented in BOR syndrome, hinting at broader congenital tissue-patterning disruptions. EyeWiki

9. Poland Anomaly
   Ipsilateral CHRRPE and Poland anomaly (chest wall underdevelopment) suggest possible shared embryonic vascular or mesodermal defects. EyeWiki

10. Juvenile Nasopharyngeal Angiofibroma
    A handful of cases describe CHRRPE concurrent with juvenile nasopharyngeal angiofibroma, indicating a possible syndromic vascular proliferation propensity. EyeWiki

11. Familial Predisposition
    A family report of three siblings with bilateral CHRRPE suggests that, in rare instances, unknown genetic factors may underlie hereditary clustering. ScienceDirect

12. Optic Nerve Head Pits
    Co-occurrence of optic disc pits and CHRRPE in isolated cases may reflect localized developmental abnormalities of the optic nerve head region. PMC

13. Optic Nerve Head Drusen
    Similarly, associations with optic nerve drusen imply that anomalous axonal transport or disc development can accompany retinal hamartomatous changes. PMC

14. X-Linked Juvenile Retinoschisis
    Rare overlap with X-linked retinoschisis highlights how vitreoretinal traction disorders and hamartoma formation may occasionally coincide. PMC

15. Choroidal Neovascularization (Secondary)
    In some CHRRPE cases, secondary choroidal neovascular membranes develop at the lesion margins, reflecting local ischemia or growth-factor upregulation. PMC

---

Symptoms

1. Painless Vision Loss
   CHRRPE typically causes a gradual, painless decrease in acuity, most notable when lesions involve the macula or optic disc. EyeWiki

2. Decreased Visual Acuity
   Up to 40 % of patients present with reduced acuity (e.g., worse than 20/40), reflecting distortion of central retinal architecture. AAO Journal

3. Strabismus
   Misalignment of the eyes (strabismus) occurs in roughly one-quarter to one-third of pediatric CHRRPE cases, often prompting the initial ophthalmic evaluation. EyeWiki

4. Metamorphopsia
   Patients may report wavy or distorted vision (metamorphopsia) due to epiretinal membrane traction on the macula. WebEye

5. Amblyopia (Lazy Eye)
   When CHRRPE disrupts visual development in one eye, amblyopia can ensue, underscoring the importance of early detection in children. EyeWiki

6. Floaters
   Vitreous traction or minor hemorrhages from abnormal vessels can produce visible floaters in the affected eye. PubMed

7. Ocular Irritation
   Some patients describe nonspecific discomfort or a gritty sensation, particularly if the lesion induces low-grade inflammation. EyeWiki

8. Visual Distortion from Membrane Formation
   The overlying epiretinal membrane can cause retinal folds or striae, leading to intermittent distortion of vision. EyeWiki

9. Scotomas (Blind Spots)
   Localized areas of reduced or absent vision (scotomas) may align with regions of severe retinal disorganization. EyeWiki

10. Asymptomatic Presentation
    Remarkably, up to two-thirds of CHRRPE cases may be found incidentally during routine eye exams, as many patients remain symptom-free. WebEye

---

Diagnostic Tests

Physical Examination

1. Visual Acuity Testing
   Measurement with a Snellen or LogMAR chart quantifies the degree of central vision loss, a key initial assessment in CHRRPE. EyeWiki

2. Cover–Uncover Test
   Evaluates binocular alignment to detect strabismus secondary to unilateral vision loss or suppression. EyeWiki

3. Slit-Lamp Biomicroscopy
   Allows detailed inspection of the vitreoretinal interface, revealing epiretinal membranes or surface wrinkling. EyeWiki

4. Dilated Fundus Examination
   Indirect ophthalmoscopy under mydriasis visualizes the lesion’s elevation, pigmentation, and vascular tortuosity. EyeWiki

5. Examination Under Anesthesia (EUA)
   In young or noncommunicative children, EUA permits comprehensive retinal evaluation without movement artifacts. EyeWiki

Manual Tests

6. Amsler Grid Test
   A simple square-grid pattern used to detect central metamorphopsia produced by macular traction.

7. Goldmann Perimetry
   Manual visual field mapping uncovers scotomas corresponding to areas of retinal disruption.

8. Ishihara Color Vision Test
   Screens for subtle color vision deficits that may accompany retinal pigment disturbances.

9. Contrast Sensitivity Testing
   Quantifies the ability to discern low-contrast stimuli, often reduced when macular architecture is altered.

Laboratory & Pathological Tests

10. Genetic Testing for NF2
    Recommended when bilateral CHRRPE is seen, to confirm or exclude neurofibromatosis type 2. PMC

11. Genetic Testing for NF1
    Considered if CHRRPE co-occurs with other NF1 stigmata such as café-au-lait spots or neurofibromas. EyeWiki

12. Genetic Testing for TSC1/TSC2
    Employed when retinal hamartomas appear alongside cortical tubers or facial angiofibromas, suggesting tuberous sclerosis. PMC

13. Histopathological Analysis
    Examination of excised tissue reveals disorganized glial, vascular, and RPE elements, confirming CHRRPE. EyeWiki

Electrodiagnostic Tests

14. Full-Field Electroretinography (ffERG)
    Assesses global retinal function, which is usually normal outside the lesion area.

15. Multifocal ERG (mfERG)
    Maps localized retinal electrophysiological responses, detecting macular dysfunction over CHRRPE.

16. Visual Evoked Potentials (VEP)
    Evaluates the integrity of the entire visual pathway from retina to cortex, typically unremarkable in isolated CHRRPE.

Imaging Tests

17. Fundus Photography
    Provides color-documented images of lesion size, location, and vascular features for longitudinal comparison. WebEye

18. Optical Coherence Tomography (OCT)
    Cross-sectional retinal imaging reveals epiretinal membrane, inner retinal disorganization, and membrane thickness. EyeWikiPMC

19. Fundus Fluorescein Angiography (FFA)
    Highlights vascular abnormalities—early hypofluorescence from pigmented areas and late leakage from tortuous vessels. EyeWiki

20. B-Scan Ultrasonography
    Illustrates lesion elevation and rules out deeper choroidal masses; useful when media opacity limits fundus view. PubMed

Non-Pharmacological Treatments

(Exercise Therapies, Mind-Body, Educational Self-Management)

1. Convergence Exercises
   Description: Guided eye-focusing exercises aimed at improving the ability to converge both eyes on a near target.
   Purpose: Enhance binocular coordination and reduce strain caused by retinal distortion.
   Mechanism: Repeated convergence builds oculomotor muscle endurance and neural pathways for coordinated eye movements Wikipedia.

2. Saccadic Training
   Description: Rapid eye-movement drills between two fixed targets.
   Purpose: Improve the speed and accuracy of gaze shifts, compensating for visual field distortions.
   Mechanism: Strengthens saccadic neural circuits, enhancing retinal image stability during head movements PMC.

3. Pursuit Tracking Exercises
   Description: Slow, continuous eye tracking of a moving target.
   Purpose: Maintain smooth retinal tracking and reduce image jumpiness.
   Mechanism: Conditions the smooth pursuit system in the cerebellum and brainstem to handle epiretinal membrane-induced distortions PMC.

4. Peripheral Awareness Drills
   Description: Tasks requiring detection of objects in the peripheral visual field.
   Purpose: Compensate for central distortion by reinforcing peripheral vision usage.
   Mechanism: Promotes cortical plasticity to integrate peripheral inputs more effectively PMC.

5. Contrast Sensitivity Training
   Description: Reading and identification of letters or shapes at varying contrast levels.
   Purpose: Enhance visual clarity in low-contrast conditions common in CHRRPE-affected eyes.
   Mechanism: Stimulates retinal ganglion and cortical neurons sensitive to contrast changes PMC.

6. Vision Relaxation Techniques
   Description: Palming and guided eye breaks with gentle massage around the orbit.
   Purpose: Reduce ocular tension and discomfort from prolonged focusing.
   Mechanism: Activates the parasympathetic system, reducing ciliary muscle spasm Wikipedia.

7. Mindful Meditation
   Description: Focused-attention meditation sessions emphasizing awareness of visual sensations.
   Purpose: Alleviate anxiety and improve coping with chronic visual impairment.
   Mechanism: Modulates limbic activity, lowering stress hormones that can worsen visual perception Wikipedia.

8. Guided Imagery
   Description: Therapist-led visualization exercises involving stable, clear images.
   Purpose: Reinforce mental representation of undistorted vision to aid adaptation.
   Mechanism: Engages visual association cortex, strengthening top-down perceptual control Wikipedia.

9. Biofeedback Training
   Description: Use of real-time feedback (e.g., eye-movement sensors) to train relaxation and optimized gaze.
   Purpose: Improve control of ocular micro-movements and reduce involuntary tremor.
   Mechanism: Teaches neural circuits to stabilize gaze via reinforcement learning Wikipedia.

10. Low Vision Rehabilitation
    Description: Multidisciplinary program of occupational therapy, orientation, and mobility training.
    Purpose: Maximize remaining vision for daily activities and mobility.
    Mechanism: Provides adaptive strategies, optical aids, and environmental modifications to work around retinal distortions PMC.

11. Assistive Device Training
    Description: Instruction in the use of magnifiers, telescopic lenses, and electronic reading aids.
    Purpose: Compensate for reduced acuity and field defects.
    Mechanism: Enhances retinal image enlargement and contrast, facilitating cortical processing PMC.

12. Self-Monitoring Diaries
    Description: Daily logging of visual symptoms, lighting conditions, and activities.
    Purpose: Identify triggers of visual discomfort and track disease stability.
    Mechanism: Encourages patient engagement and data-driven adjustment of therapy AAO.

13. Educational Workshops
    Description: Group classes on CHRRPE, self-management, and coping strategies.
    Purpose: Empower patients with knowledge and peer support.
    Mechanism: Increases self-efficacy and adherence to rehabilitation plans AAO.

14. Tele-Rehabilitation
    Description: Remote vision exercises and counseling via video conferencing.
    Purpose: Ensure continuity of care when in-person visits are impractical.
    Mechanism: Uses digital platforms to deliver personalized guided therapy and monitor progress AAO.

15. Adaptive Computer Software
    Description: Screen-reading and magnification software with customizable contrast and font.
    Purpose: Facilitate computer use for work and education.
    Mechanism: Modifies digital content to match remaining visual function American Osteopathic Association.

16. Environmental Modifications
    Description: Optimizing home and workspace lighting, contrast, and arrangement.
    Purpose: Reduce glare and maximize residual vision.
    Mechanism: Alters visual environment to minimize stress on distorted retinal areas American Osteopathic Association.

17. Psychological Counseling
    Description: Individual therapy addressing emotional impact of vision loss.
    Purpose: Prevent depression and anxiety associated with chronic ocular disease.
    Mechanism: Cognitive-behavioral techniques restructure negative thought patterns PMC.

18. Support Groups
    Description: Peer-led meetings for sharing experiences and coping tips.
    Purpose: Foster social support and knowledge exchange.
    Mechanism: Group dynamics enhance motivation and reduce isolation PMC.

19. Energy Conservation Training
    Description: Techniques for pacing daily tasks and reducing visual fatigue.
    Purpose: Maintain function throughout the day without exacerbating symptoms.
    Mechanism: Teaches planning and prioritization to align activities with peak visual performance Centers for Medicare & Medicaid Services.

20. Vision Self-Efficacy Coaching
    Description: Goal-setting and problem-solving training led by rehabilitation specialists.
    Purpose: Build confidence in managing visual challenges.
    Mechanism: Uses motivational interviewing and mastery experiences to reinforce adaptive behaviors AAO.

---

Pharmacological Treatments

(Evidence-Based Drugs for CHRRPE-Related Complications)

1. Bevacizumab (Avastin)
   A monoclonal anti-VEGF antibody administered as 1.25 mg intravitreal injections every 4–6 weeks to treat preretinal neovascularization and vitreous hemorrhage secondary to CHRRPE. Side effects include transient intraocular pressure rise and rare endophthalmitis PMCWikipedia.

2. Ranibizumab (Lucentis)
   A fragment of anti-VEGF antibody given at 0.5 mg intravitreally monthly for macular edema associated with tractional membranes. Risks mirror those of intravitreal injections, including floaters and infection PMC.

3. Aflibercept (Eylea)
   A VEGF-trap fusion protein injected at 2 mg every 8 weeks to reduce vascular leakage. Side effects: hypertension, ocular hemorrhage, and injection-related discomfort PMC.

4. Triamcinolone Acetonide
   A corticosteroid (4 mg intravitreal) administered single dose to decrease macular edema and membrane inflammation. Common side effects: cataract progression and intraocular pressure elevation Healio Journals.

5. Dexamethasone Implant (Ozurdex)
   A biodegradable intravitreal implant releasing 0.7 mg dexamethasone over 4 months. Used for persistent macular thickening. Watch for glaucoma and cataracts Healio Journals.

6. Pegaptanib (Macugen)
   A 0.3 mg intravitreal aptamer targeting VEGF-165 isoform, injected every 6 weeks for neovascular complications. Side effects include eye pain and photophobia Wikipedia.

7. Topical Nepafenac (Nevanac)
   0.1% ophthalmic solution three times daily to reduce mild perioperative inflammation and cystoid changes. Side effects: ocular irritation and superficial punctate keratitis Wikipedia.

8. Topical Bromfenac (Prolensa)
   A once-daily NSAID drop to limit inflammatory mediators. Caution in corneal epithelial defects Wikipedia.

9. Oral Acetazolamide
   250 mg twice daily to decrease intraocular fluid production in cases of secondary ocular hypertension. Side effects: paresthesia, malaise, and metabolic acidosis Wikipedia.

10. Oral Prednisone
    Systemic 1 mg/kg tapered over weeks for severe inflammatory complications. Monitor blood glucose and bone density Healio Journals.

---

 Dietary Molecular Supplements

(Dosage, Function, Mechanism)

1. Lutein (10 mg/day)
   A macular xanthophyll that filters blue light and reduces oxidative stress in photoreceptors Wikipedia.

2. Zeaxanthin (2 mg/day)
   Works synergistically with lutein to protect retinal cells via antioxidant and anti-inflammatory effects Wikipedia.

3. Vitamin C (500 mg/day)
   A water-soluble antioxidant that neutralizes free radicals in the vitreous and retina Wikipedia.

4. Vitamin E (400 IU/day)
   Fat-soluble antioxidant preserving photoreceptor membrane integrity Wikipedia.

5. Zinc (80 mg/day)
   Essential cofactor for superoxide dismutase; supports retinal pigment epithelium health Wikipedia.

6. Copper (2 mg/day)
   Prevents zinc-induced anemia and supports antioxidant enzyme function Wikipedia.

7. Omega-3 Fatty Acids (EPA/DHA 1000 mg/day)
   Incorporates into photoreceptor membranes, enhances fluidity, and exerts anti-inflammatory effects PMC.

8. Bilberry Anthocyanins (160 mg twice daily)
   Increases antioxidant defense, suppresses proinflammatory cytokines, and inhibits retinal cell apoptosis PMCRxList.

9. Resveratrol (100 mg/day)
   Activates sirtuins and induces neuroprotective pathways in the retina bmjophth.bmj.com.

10. Alpha-Lipoic Acid (200 mg/day)
    Regenerates other antioxidants and reduces oxidative damage to retinal neurons JAMA Network.

---

Regenerative (Stem Cell) Therapies

(Dosage, Function, Mechanism)

1. iPSC-Derived RPE Cells
   Subretinal injection of 200,000 cells; replace damaged RPE, secrete trophic factors to support photoreceptors PMC.

2. Human Retinal Progenitor Cells
   Intravitreal injection of 1×10^6 cells; provide neuroprotection and modulate local inflammation Fighting Blindness Canada (FBC).

3. Bone Marrow-Derived MSCs
   Intravitreal 5×10^5 CD34+ cells; home to damaged retina, release growth factors that inhibit apoptosis UC Davis Health.

4. OpCT-001 (iPSC-Derived Photoreceptors)
   Subretinal administration of 150,000 cells; integrate into neural retina and restore phototransduction pathways Fighting Blindness Canada (FBC).

5. ESC-Derived RPE Patch
   Surgical implantation of a monolayer sheet; physically replaces RPE and provides barrier/transport functions ClinicalTrials.gov.

6. Neurotrophic Stem Cell Secretome
   Intravitreal injection of concentrated MSC-conditioned medium weekly for 4 weeks; supplies cytokines and exosomes to promote regeneration PMC.

---

Surgical Interventions

(Procedure, Benefits)

1. Pars Plana Vitrectomy & Epiretinal Membrane Peeling
   Removal of vitreous gel and tractional membrane under microscope; relieves vessel distortion and improves macular contour PMC.

2. Internal Limiting Membrane (ILM) Peeling
   Fine peeling of the innermost retinal layer after dye staining; reduces recurrence of membrane formation and stabilizes vision PMC.

3. Macular Translocation Surgery
   Repositioning of the macula to healthier retina via 360° retinotomy; indicated in severe macular distortion to restore central vision alignment PMCPMC.

4. Laser Photocoagulation
   Focal application of thermal burns to the lesion periphery; aims to shrink vascular components and prevent neovascular complications PMC.

5. Cryotherapy
   Freezing probe applied externally to lesion base; induces sclerosis of abnormal vessels and stabilizes tumor growth clinically PMC.

---

Preventive Strategies

1. Genetic Counseling
   For families with NF1/NF2 history; early detection and monitoring of CHRRPE risk PMC.

2. Prenatal Folic Acid
   May reduce general congenital ocular anomalies Verywell Health.

3. Avoid Maternal Teratogens
   Abstain from alcohol, tobacco, and certain medications during pregnancy Verywell Health.

4. Protective Eyewear
   Use UV-blocking sunglasses outdoors to prevent additional retinal damage Verywell Health.

5. Healthy Mediterranean-Style Diet
   Rich in fruits, vegetables, and omega-3s to support retinal health Verywell Health.

6. Routine Pediatric Eye Exams
   Early detection of visual abnormalities and strabismus PMC.

7. Control of Systemic Inflammation
   Manage autoimmune or infectious conditions that could exacerbate ocular lesions PMC.

8. Maintain Healthy Weight
   Reduces risk of comorbidities that can affect ocular microcirculation Verywell Health.

9. Smoking Cessation
   Decreases oxidative stress on retinal tissues Verywell Health.

10. Regular UV-Safety Checks
    Ensure eyewear continues to block harmful radiation over time Verywell Health.

---

When to See a Doctor

Immediately consult an ophthalmologist if you experience sudden vision loss, new floaters or flashes, worsening distortion, strabismus onset, or signs of vitreous hemorrhage (dark shadows or haze) PMC. Early evaluation with OCT, FFA, and ultrasound can distinguish CHRRPE from malignancies and guide timely intervention PMC.

---

What to Do and What to Avoid

1. Do: Attend scheduled low-vision rehabilitation sessions.

2. Avoid: Rubbing or pressing the eye, especially post-injection Wikipedia.

3. Do: Maintain a symptom diary to report changes promptly.

4. Avoid: Unsanctioned use of over-the-counter eye drops.

5. Do: Use recommended optical aids daily.

6. Avoid: High-impact sports without protective eyewear.

7. Do: Eat a balanced diet rich in retinal antioxidants.

8. Avoid: Excessive screen time without proper breaks.

9. Do: Follow ophthalmologist’s instructions for intravitreal injections.

10. Avoid: Swimming or eye submersion for 48 hours after procedures Wikipedia.

---

Frequently Asked Questions (FAQs)

1. What causes combined hamartoma of the retina?
   It arises from congenital malformation of retinal and RPE cells; sometimes linked to syndromes like NF2 PMC.

2. Is CHRRPE cancerous?
   No; it is a benign tumor, though it can mimic melanoma or retinoblastoma clinically PMC.

3. Can one eye or both eyes be affected?
   It is most often unilateral, but bilateral cases occur, especially in syndromic presentations PMC.

4. What is the prognosis?
   Vision depends on lesion location; extramacular lesions have better outcomes than macular involvement PMC.

5. Can it progress after childhood?
   Lesion growth is typically slow; regular monitoring is essential to catch complications early ophthalmologyretina.org.

6. Are there non-surgical options?
   Yes—vision therapy, intravitreal anti-VEGF, and low-vision aids can stabilize function PMC.

7. When is surgery indicated?
   For tractional complications like membrane formation causing visual distortion or detachment PMC.

8. Can CHRRPE recur after surgery?
   Epiretinal membranes may regrow, necessitating ILM peeling to reduce recurrence PMC.

9. Is genetic testing recommended?
   In syndromic cases (NF1/NF2), genetic evaluation can guide family planning PMC.

10. Do supplements help?
    Nutrients like lutein, zeaxanthin, and omega-3s support retinal health but do not cure CHRRPE Wikipedia.

11. What imaging is used for diagnosis?
    OCT, FFA, ultrasound, and MRI help characterize the lesion and exclude malignancy PMC.

12. Can vision improve without surgery?
    Some patients adapt via rehabilitation and may experience subjective improvements PMC.

13. Is laser treatment effective?
    Focal laser can shrink vascular anomalies but is adjunctive rather than primary therapy PMC.

14. How often should I follow up?
    Every 3–6 months if stable; more frequently if complications arise PMC.

15. Where can I find support?
    Low-vision clinics, patient associations, and online forums offer resources and community PMC.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 19, 2025.